Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Unintended human messenger RNAs (mRNAs) with partial complementarity to short hairpin RNA (shRNA) seed regions represent a major class of off-target effects in RNA interference (RNAi) technology. These mRNAs are inadvertently silenced when the seed region, comprising nucleotides 2 through 8 of the shRNA-derived guide strand, binds to their 3' untranslated regions (UTRs) with partial complementarity (Jackson et al., 2003; Birmingham et al., 2006). This interaction mimics the natural regulatory mechanism of microRNAs (miRNAs), resulting in unintended translational repression or mRNA degradation. Such off-target silencing can lead to significant cellular toxicity, altered experimental phenotypes, and safety risks in clinical applications, most notably hepatotoxicity (Grimm et al., 2006). In the context of drug development, these interactions are a primary hurdle, necessitating rigorous bioinformatic screening and chemical modifications to the RNA backbone to enhance specificity. Furthermore, high levels of shRNA expression can saturate the endogenous RNAi machinery, such as Exportin-5 and the RNA-induced silencing complex (RISC), which compounds the toxic effects (Grimm et al., 2006). Consequently, identifying and avoiding these unintended mRNA interactions is essential for the design of safe and effective RNAi-based therapeutics (Setten et al., 2019). This phenomenon highlights the importance of sequence specificity beyond the intended target site in the development of nucleic acid-based medicines.
Seed-mediated RNA interference (RNAi) involving the binding of the shRNA/siRNA guide strand seed region (nucleotides 2-8) to partially complementary sequences in the 3' UTR of unintended mRNAs, leading to miRNA-like gene silencing (Jackson et al., 2003; Birmingham et al., 2006).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Unintended human messenger RNAs with partial complementarity to short hairpin RNA (shRNA) seed regions.